Cwm, LLC Ligand Pharmaceuticals Inc Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Cwm, LLC holds 203 shares of LGND stock, worth $24,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares

203

Previous 196 3.57%

Holding current value

$24,908

Previous $17,000 17.65%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$82.7 - $110.11 $578 - $770	7 Added 3.57%	203 $20,000
Q2 2024 Jul 09, 2024	SELL	$68.53 - $87.91 $6,715 - $8,615	-98 Reduced 33.33%	196 $17,000
Q1 2024 Apr 05, 2024	SELL	$68.64 - $89.2 $6,932 - $9,009	-101 Reduced 25.57%	294 $21,000
Q4 2023 Feb 01, 2024	BUY	$49.57 - $72.63 $198 - $290	4 Added 1.02%	395 $28,000
Q3 2023 Oct 11, 2023	BUY	$58.86 - $72.67 $11,830 - $14,606	201 Added 105.79%	391 $23,000
Q2 2023 Aug 03, 2023	BUY	$69.53 - $79.33 $486 - $555	7 Added 3.83%	190 $14,000
Q1 2023 Apr 28, 2023	BUY	$65.67 - $77.08 $459 - $539	7 Added 3.98%	183 $13,000
Q4 2022 Feb 01, 2023	BUY	$61.72 - $96.74 $1,049 - $1,644	17 Added 10.69%	176 $12,000
Q2 2022 Jul 28, 2022	BUY	$74.52 - $117.06 $4,396 - $6,906	59 Added 59.0%	159 $14,000
Q1 2022 Apr 21, 2022	SELL	$94.99 - $151.56 $3,134 - $5,001	-33 Reduced 24.81%	100 $11,000
Q4 2021 Jan 31, 2022	BUY	$127.69 - $165.85 $14,301 - $18,575	112 Added 533.33%	133 $21,000
Q3 2020 Oct 19, 2020	BUY	$89.56 - $126.72 $1,701 - $2,407	19 Added 950.0%	21 $2,000
Q2 2019 Jul 31, 2019	SELL	$107.38 - $129.34 $214 - $258	-2 Reduced 50.0%	2 $0
Q1 2019 Apr 22, 2019	BUY	$105.93 - $142.47 $211 - $284	2 Added 100.0%	4 $1,000
Q3 2017 Oct 16, 2017	BUY	$120.91 - $137.94 $241 - $275	2	2 $0

Others Institutions Holding LGND

# of Institutions

257

Shares Held

18.2M

Call Options Held

26.8K

Put Options Held

9.3K

View Full List

About LIGAND PHARMACEUTICALS INC

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $2.07B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

More about LGND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account